Efficacy and tolerability of low-dose donepezil in schizophrenia

Clinical Neuropharmacology

Volumn 28, Issue 4, 2005, Pages 179-184

  Erickson, Steven K ^a   Schwarzkopf, Steven B ^a   Palumbo, Donna ^a   Badgley Fleeman, Jennifer ^b   Smirnow, Alexis M ^a   Light, Gregory A ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NEW YORK STATE OFFICE OF MENTAL HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cognition; Donepezil; Negative symptoms; Schizophrenia

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL;

ACETYLCHOLINE RELEASE; ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MENTAL DISEASE; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ACETYLCHOLINE; ADULT; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VERBAL LEARNING;

EID: 23644433690     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000173714.61744.e6     Document Type: Article

References (45)

1. Wyatt R, Henter I, Leary M, et al. An economic evaluation of schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 1991;30:196-205.
2. Sevy S, Davidson M. The cost of cognitive impairment in schizophrenia. Schizophr Res. 1995;17:1-3.
3. Green M. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
4. Silverstein S, Schenkel L, Valone C, et al. Cognitive deficits and psychiatric rehabilitation outcomes in schizophrenia. Psychiatr Q. 1998;69:169-191.
5. Stip E, Chouinard S, Boulay L. On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog Nenropsychopharmacol Biol Psychiatry. 2005;29:219-232.
6. Mortimer AM. Cognitive function in schizophrenia-do neuroleptics make a difference? Pharmacol Biochem Behav. 1997;56:789-795.
7. King DJ. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry. 1990;157:799-811.
8. Green M. Schizophrenia from a neurocognitive perspective: probing the impenetrable darkness. Boston: Pearson Allyn & Bacon; 1997.
9. Potkin S, Basile V, Jin Y, et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry. 2003;8:109-113.
10. Aghajanian G, Marek G. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev. 2000;31:302-312.
11. Tuominen H, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2005;72:225-234.
12. Crook JM, Tomaskovic-Crook E, Copolov DL, et al. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry. 2000;48:381-388.
13. Freedman R, Adams CE, Leonard S. The alpha-7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanat. 2000;20:299-306.
14. Lindstrom J. Nicotine acetylcholine receptors in health and disease. Mol Neurobiol. 1997;15:193-222.
15. Breese C, Lee M, Adams C, et al. Abnormal regulation of high affinity nicotine receptors in subjects with schizophrenia. Neuropsychopharmacology. 2000;23:351-364.
16. Haroutunian V, Davidson M, Kanof P, et al. Cortical cholinergic markers in schizophrenia. Schizophr Res. 1994;12:137-144.
17. Freedman R, Hall M, Adler LE, et al. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 1995;38:22-33.
18. Karson C, Mrak R, Husain M, et al. Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions. Mol Chem Neuropathol. 1996;29:181-191.
19. Shioiri T, Hamakawa H, Kato T, et al. Proton magnetic resonance spectroscopy of the basal ganglia in patients with schizophrenia: a preliminary report. Schizophr Res. 1996;22:19-26.
20. Levin E, Wilson W, Rose J, et al. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 1996;15:429-436.
21. Smith R, Singh A, Infante M, et al. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology. 2002;27:479-493.
22. Adler L, Hoffer L, Wiser A, et al. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 1993;150:1856-1861.
23. Stevens KE, Meltzer J, Rose GM. Nicotinic cholinergic normalization of amphetamine-induced loss of auditory gating in freely moving rats. Psychopharmacology (Berl). 1995;119:163-170.
24. Brauder L, Cramblett M, Paxton D, et al. Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes. Psychopharmacology (Berl). 2001;159:31-37.
25. Arnold H, Nelson C, Sarter M, et al. Sensitization of cortical acetylcholine release by repeated administration of nicotine in rats. Psychopharmacology (Berl). 2003;165:346-358.
26. Dursun S, Kutcher S. Smoking, nicotine and psychiatric disorders: evidence for therapeutic role, controversies and implications for future research. Med Hypotheses. 1999;52:101-109.
27. Buchanan R, Francis A, Arango C, et al. Morphometric assessment of the heteromodal association cortex in schizophrenia. Am J Psychiatry. 2004;161:322-331.
28. Zekry D, Duyckaerts C, Belmin J, et al. The vascular lesions in vascular and mixed dementia: the weight of functional neuroanatomy. Neurobiol Aging. 2001;24:213-219.
29. Garrido G, Furuie C, Buchpiguel C, et al. Relation between medial temporal atrophy and functional brain activity during memory processing in Alzheimer's disease: a combined MRI and SPECT study. J Neurol Neurosurg Psychiatry. 2002;73:508-516.
30. Jann M, Shirley K, Small G. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41:719-739.
31. Bryson H, Benfield P. Donepezil. Drugs Aging. 1997;10:234-239.
32. Rogers S, Friedhoff L. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293-303.
33. Cummings J, Gorman D, Shapira J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry. 1993;33:536-541.
34. White K, Cummings J. Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. Compr Psychiatry. 1996;37:188-195.
35. Buchanan R, Summerfelt A, Tek C, et al. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res. 2003;59:29-33.
36. Stryjer R, Strous RD, Bar F, et al. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropsychopharmacol. 2003;26:12-17.
37. Nahas A, George MS, Markowitz JS, et al. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase. 2003;9:274-282.
38. MacEwan GW, Ehmann TS, Khanbhai I, et al. Donepezil in schizophrenia-is it helpful? An experimental design case study. Acta Psychiatr Scand. 2001;104:469-472.
39. Friedman JI, Adler DN, Howanitz E, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry. 2002;51:349-357.
40. Caroff S, Campbell E, Havey J, et al. Treatment of tardive dyskinesia with donepezil: a pilot study. J Psychiatry. 2001;62:772-775.
41. First M, Spitzer R, Gibbon M, et al. Structured clinical interview for DSM IV Axis I disorders-patient edition (SCID-I/P). New York: Biometrics Research Department, New York Psychiatric Institute; 1995.
42. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
43. Holt DJ, Herman MM, Hyde TM, et al. Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience. 1999;94:21-31.
44. Moore H, Fadel J, Sarter M, et al. Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release. Neuroscience. 1999;88:811-822.
45. Friedman JI, Adler DN, Howanitz E, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry. 2002;51:349-357.